SJ04 not checked
Suzhou Centergene Pharmaceuticals Co.,Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “T: SJ04 (Test drug) R: Ovidrel® (Referecne drug) 250 μg of SJ04 injection or Oviderl®, administered subcutaneously once at two week intervals.”In the company’s words, NCT06599528 on ClinicalTrials.gov
- Tested for
- Assisted Reproductive Technology, Female Infertility
- Main trialPhase 1
- “This is a single-centre, randomised, open-label, single-dose, two-cycle, double-crossover study to compare the pharmacokinetics of SJ04 and Ovidrel® in healthy female subjects. Received a single subcutaneous injection administration of SJ04 Injection or Ovidrel®, both administered at a dose of 250 μg, once per cycle, and cross-administered after a washout period.”In the company’s words, NCT06599528 on ClinicalTrials.gov
Other drugs for Female Infertility
- MibavademabRegeneron · Phase 2
- QL1012DQilu Pharmaceutical · Phase 1
- Fang Le ShuLG Chem · Marketed (Phase 4 trial)
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 30 Jun 2026 | A Comparing Study Between SJ04 and Ovidrel® in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026